MEDIF Stock Chart & Stats
$0.06
>-$0.01(-5.26%)
At close: 4:00 PM EDT
$0.06
>-$0.01(-5.26%)
Day’s Range― - ―
52-Week Range$0.04 - $0.08
Previous CloseN/A
Volume23.34K
Average Volume (3M)49.06K
Market Cap
$21.36M
Enterprise Value$20.36
Total Cash (Recent Filing)$9.85M
Total Debt (Recent Filing)$421.00K
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Nov 16, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,177,150
10 Day Avg. Volume35,584
30 Day Avg. Volume49,056
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$28.34M
Bulls Say, Bears Say
Bulls Say
Return To ProfitabilityThe return to quarterly profitability and consecutive positive adjusted EBITDA indicate that restructuring and operating improvements are translating into earnings. If sustained, this recovery can strengthen internal funding capacity, validate the business model, and improve financial resilience over the next several quarters.
Margin Expansion And Cost DisciplineHigher gross margins combined with sharply lower operating expenses demonstrate meaningful cost discipline and improved unit economics. These gains can provide a durable base for earnings growth because incremental revenue may contribute more effectively to profit while management maintains a leaner cost structure.
Low Leverage And Financial FlexibilityA cash balance, minimal debt burden, and owned production assets give MediPharm flexibility to fund operations and targeted expansion without relying heavily on borrowing. This reduces solvency risk and preserves strategic options while the company continues its profitability turnaround.
Bears Say
Declining Revenue And Incomplete Profitability RecoveryRevenue contraction and continued negative operating and EBITDA margins show that the turnaround has not yet become durable across the full business. Until growth resumes and operating profit is sustained, earnings quality remains vulnerable and the company has less capacity to absorb market or execution challenges.
Negative Cash GenerationNegative operating and free cash flow mean the business is not yet self-funding, even though cash burn has improved from 2025. Continued cash deficits can constrain investment, increase dependence on liquidity management, and delay the point at which operational recovery translates into durable financial strength.
Reimbursement And Regulatory PressureThe reimbursement reduction has already lowered Canadian medical revenue, while pricing pressure and regulatory scrutiny create additional risks in important markets. These forces can compress realized pricing, weaken channel economics, and make international and medical growth less predictable over the medium term.
MediPharm Labs News
MEDIF FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was $0.04 and its highest was $0.07 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is $21.36M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Nov 16, 2026 which is in 58 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.002 by $0.002.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 427,177,150 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of $0 in its last earnings report, beating expectations of -$0.002. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in MEDIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.
MEDIF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial recovery: return to profitability, highest adjusted EBITDA since 2019, robust margin expansion, meaningful sequential revenue growth driven by international markets (notably Germany), successful Phase II LiBBY clinical results validating the pharmaceutical platform, and balance sheet strength. Headwinds include a material 30% VAC reimbursement cut that reduced Canadian medical revenue, ongoing pricing pressure and competition in key markets (Germany), and broader prescribing/reimbursement uncertainties. Overall, the positive operational execution, clinical validation, and improved profitability notably outweigh the identified challenges.View all MEDIF earnings summaries